

Abstract

Brain targeting: optimisation and biocompatibility of valproic acid-loaded nanostructured lipid carriers (VPA-NLC) for nose-to-brain delivery[†]

Armanda do Carmo Correia (A.C.C.)¹, Inês Costa (I. C.)², Renata Silva (R. S.)², João Nuno Moreira (J.N.M.)³, José Manuel Sousa Lobo (J.M.S.L.)¹, Ana Catarina Silva (A.C.S.)^{1,4*}

¹ UCIBIO, REQUIMTE, MEDTECH, Laboratory of Pharmaceutical Technology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, Porto, Portugal; Associate Laboratory i4HB Institute for Health and Bioeconomy, Faculty of Pharmacy, University of Porto, Porto, Portugal.; A.C.C.: adocarmocorreia@gmail.com; J.M.S.L.: slobo@ff.up.pt; A.C.S.: anacatsil@gmail.com

² UCIBIO, REQUIMTE, Laboratory of Toxicology, Department of Biological Sciences, Faculty of Pharmacy, Porto University, Porto, Portugal. Associate Laboratory i4HB Institute for Health and Bioeconomy, Faculty of Pharmacy, University of Porto, Porto, Portugal.; I. C.: inessilvacosta@hotmail.com; R. S.: rsilva@ff.up.pt

³ CNC - Center for Neuroscience and Cell Biology, Center for Innovative Biomedicine and Biotechnology (CIBB), Faculty of Medicine (Pólo I), University of Coimbra, 3004-531 Coimbra, Portugal; Univ Coimbra - University of Coimbra, CIBB, Faculty of Pharmacy, Pólo das Ciências da Saúde, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal.; jmoreira@ff.uc.pt

⁴ FP-IBID (Instituto de Investigação, Inovação e Desenvolvimento), FP-BHS (Biomedical and Health Sciences Research Unit), Faculty of Health Sciences, University Fernando Pessoa, 4249 004 Porto, Portugal; anacatsil@gmail.com

* Correspondence: anacatsil@gmail.com

† Presented at the title, place, and date.

Abstract: The nose-to-brain route is one of the most promising alternative to promote drug delivery to the brain in the treatment of neurological diseases. Nasally administered drugs can be directly transported through the olfactory and trigeminal nerves, but enzymatic activity and the mucociliary clearance limit this process. Encapsulation of drugs in lipid nanoparticles, such as nanostructured lipid carriers (NLC), protects molecules against enzymatic activity, while promotes direct nose-to-brain transport.

In this work, a valproic acid-loaded NLC (VPA-NLC) formulation was optimised using the quality-by-design (QbD) approach. A mixture design and a central composite design were used to optimise the critical material attributes (CMAs) and the critical process parameters (CPPs), respectively. The *in vitro* drug release profile and VPA-NLC morphology were investigated. The biocompatibility was assessed in human neuronal and nasal epithelial cells. VPA-NLC showed a particle size of 75 ± 1.05 nm, a polydispersity index (PDI) of 0.179 ± 0.006 , an encapsulation efficiency (EE) of 85.7 % and a zeta potential (ZP) of 27.4 ± 0.351 mV. Transmission electron microscopy (TEM) images showed spherical nanoparticles smaller than 100 nm. Drug release studies showed about 50% of drug release after 6 hours and 100% after 24h. The VPA-NLC revealed safety up to 75 $\mu\text{g/mL}$ in both cell lines. The optimised VPA-NLC formulation met the criteria of small particle size and PDI, and high EE and absolute ZP, which are required to follow the direct nose-to-brain transport. Additional experiments are being carried out to predict the *in vivo* safety and effectiveness of this formulation.

Keywords: Design of experiment; intranasal; nanostructured lipid carriers; nose-to-brain; quality by design; valproic acid.

Citation: Correia A. C.; Moreira, J. N.; Lobo, J. M., Silva A. C. Brain targeting: . *Med. Sci. Forum* **2023**, *2*, x. <https://doi.org/10.3390/xxxxx>

Academic Editor: Firstname Last-name

Published: date

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2023 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Supplementary Materials: Not applicable.	1
Author Contributions: Conceptualization, A.C.C. and A.C.S.; methodology, A.C.C., I. C. and R. S.; investigation, A.C.C., I. C. and R. S.; writing—original draft preparation, A.C.C. and A.C.S.; writing—review and editing, A.C.S., J.N.M. and J.M.S.L.. All authors have read and agreed to the published version of the manuscript.	2 3 4 5
Funding: This research was funded by PT national funds (FCT/MCTES, Fundação para a Ciência e Tecnologia and Ministério da Ciência, Tecnologia e Ensino Superior) through the project UIDB/04378/2020 and UIDP/04378/2020.	6 7 8
Institutional Review Board Statement: Not applicable.	9
Informed Consent Statement: Not applicable.	10
Data Availability Statement: Not applicable.	11
Acknowledgments: This work was supported by the Applied Molecular Biosciences Unit-UCIBIO (UIBD 151315/2020).	12 13
Conflicts of Interest: The authors declare no conflict of interest.	14
The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.	15 16 17